Abstract:Background The pathogenesis of post-stroke depression (PSD) remains largely unknown. There is growing evidence indicating that gut microbiota participates in the development of brain diseases through the gut-brain axis. Here, we aim to determine whether and how microbial composition and function altered among control, stroke and PSD rats. Materials and Methods After the PSD rat model was successfully established, gut microbiome combined with fecal metabolome approach were performed to identify potentially PSD-related gut microbes and their functional metabolites. Then, correlations between behavior indices and altered gut microbes, as well as correlations between altered gut microbial operational taxonomic units (OTUs) with differential metabolites in PSD rats were explored. Enrichment analysis was also conducted to uncover the crucial metabolic pathways related to PSD. Results Although there were some alterations in the microbiome and metabolism of the control and stroke rats, we found that the microbial and metabolic phenotypes of PSD rats were significantly different. The microbial composition of PSD showed a decreased species richness indices, characterized by 22 depleted OTUs mainly belonging to phylum Firmicutes , genus Blautia and Streptococcus . In addition, PSD was associated with disturbances of fecal metabolomics, among them Glutamate, Maleic acid, 5-Methyluridine, Gallocatechin, 1,5-Anhydroglucitol, L-Kynurenine, Daidzein, Cyanoalanine, Acetyl Alanine and 5-Methoxytryptamine were significantly related to disturbed gut microbiome (P ≤ 0.01). Disordered fecal metabolomics in PSD rats mainly assigned to lipid, amino acid, carbohydrate and nucleotide metabolism. The steroid biosynthesis was particularly enriched in PSD. Conclusions Our findings suggest that gut microbiome may participate in the development of PSD, the mechanism may be related to the regulation of lipid metabolism.

Post-stroke depression: epigenetic and epitranscriptomic modifications and their interplay with gut microbiota

Epigenetics in depression and gut-brain axis: A molecular crosstalk

From Gut to Brain: Unraveling the Intricate Link Between Microbiome and Stroke

A potential role of gut microbiota in stroke: mechanisms, therapeutic strategies and future prospective

Novel Mechanisms and Therapeutic Targets for Ischemic Stroke: A Focus on Gut Microbiota

Role of the Gut Microbiota in Stroke Pathogenesis and Potential Therapeutic Implications

Crosstalk between the Gut and Brain in Ischemic Stroke: Mechanistic Insights and Therapeutic Options

Systematic Insights into the Relationship between the Microbiota–Gut–Brain Axis and Stroke with the Focus on Tryptophan Metabolism

Deciphering the gut microbiota's (Coprococcus and Subdoligranulum) impact on depression: Network pharmacology and molecular dynamics simulation

Microbiota-derived short-chain fatty acids may participate in post-stroke depression by regulating host's lipid metabolism

Alteration of Gut Microbiome and Correlated Lipid Metabolism in Post-Stroke Depression

Unraveling the protein post-translational modification landscape: Neuroinflammation and neuronal death after stroke

Microbiota-gut-brain axis impairment in the pathogenesis of stroke: implication as a potent therapeutic target

Gut Microbiota and Their Metabolites in Stroke: A Double-Edged Sword

Plant-derived bioactive components regulate gut microbiota to prevent depression and depressive-related neurodegenerative diseases: Focus on neurotransmitters

Exploring the pathogenesis and treatment of PSD from the perspective of gut microbiota

Gut microbiota-derived short-chain fatty acids and depression: deep insight into biological mechanisms and potential applications

Intestinal flora induces depression by mediating the dysregulation of cerebral cortex gene expression and regulating the metabolism of stroke patients

The Gut Microbiome as Therapeutic Target in Central Nervous System Diseases: Implications for Stroke

A new perspective on hippocampal synaptic plasticity and post‐stroke depression

Depression-associated gut microbes, metabolites and clinical trials